Clinical trials: Prostate Cancer Stage
Prostatic Neoplasms
Irreversible Electroporation(IRE) For Unresectable Prostatic Neoplasms
The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Prostatic Neoplasms.
- Trial name
- IRE (NCT02430649)
- Testing
- Irreversible electroporation (IRE), NanoKnife
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Prostate Cancer
Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer
Objectives to evaluate the activity of Erlotinib in prostate cancer patients who are hormone refractory and androgen independent and have not been exposed to chemotherapy.
- Trial name
- NCT00272038
- Testing
- Tarceva
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Oncology Specialists, S.C.
Prostatic Neoplasm
Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial
The purpose of this study is to determine the most appropriate radiation implant dose for palladium-103 monotherapy. Radiation dose is related to potential cure.
- Trial name
- NCT00247312
- Testing
- Pd-103
- Where
- 2 sites in United States
- Volunteers
- 319 people, healthy volunteers welcome
- Sponsor
- Schiffler Cancer Center
Cancer Survivor, Depression
Helping African American Prostate Cancer Survivors and Their Partners Cope With Challenges After Surgery for Prostate Cancer
RATIONALE: Telephone counseling after radical prostatectomy may help African American prostate cancer survivors and their intimate partners cope with the problems and challenges of surgery, and may reduce distress and improve…
- Conditions
- Cancer Survivor, Depression, Gastrointestinal Complications, Male Erectile Disorder
- Trial name
- NCT00869739
- Testing
- telephone-based intervention, educational intervention, partner-assisted coping skills training
- Where
- United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- East Carolina University
Carcinoma Prostate
Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib
Multiparametric assesment of bone response in mCRPC patients treated with Cabozantinib upon progression to chemotherapy and next generation hormonal agents: a phase II study
- Trial name
- MERIDIAN (NCT05265988)
- Testing
- Cabozantinib
- Where
- Italy
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Alfredo Berruti
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer
This early phase I trial studies how well a genetic test called pharmacogenomics works in directing the optimal use of supportive care medications in patients with stage III-IV cancer.
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
- Trial name
- NCT04067960
- Testing
- Biospecimen Collection, Genetic Testing, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 197 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Prostate Cancer
Study of a Polymorphism in Patients With Prostate Cancer
RATIONALE: Studying samples of blood from patients with cancer and from healthy participants in the laboratory may help doctors learn more about changes that may occur in DNA.
- Trial name
- NCT00900185
- Testing
- mutation analysis, polymerase chain reaction, polymorphism analysis
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)